INTRODUCTION: Omega-3 polyunsaturated fatty acids (PUFAs) have purported protective cardiovascular (CV) effects. We sought to assess the evidence available for the use of omega-3 PUFAs for the prevention of cardiovascular disease (CVD). METHODS: A systematic literature search was conducted using MEDLINE and EMBASE from 1999 to 2015. Placebo-controlled, randomized controlled trials (RCTs) that enrolled over 1000 patients with follow-up greater than 1 year and meta-analyses of RCTs were included. RESULTS: Eight RCTs and 2 meta-analyses were included. In patients with preexisting CVD, only 1 of 5 included RCTs demonstrated a reduction in CV events with omega-3 PUFAs; however, the effect size was minimal, and the study was limited by an open-label design and lack of placebo control. Two meta-analyses concluded omega-3 PUFAs do not reduce CV events in addition to standard, evidence-based therapy in patients after myocardial infarction. Of the 3 predominantly primary prevention RCTs, only 1 demonstrated a minor reduction in major coronary events; however, it was also an open-label study. Furthermore, the safety of omega-3 PUFAs should be considered. While data from RCTs have not demonstrated serious safety concerns, omega-3 PUFAs can increase the risk of bleeding and may interact with other medications that affect hemostasis, such as antiplatelet agents and warfarin. DISCUSSION AND CONCLUSION: There is currently a lack of evidence to support the routine use of omega-3 PUFAs in the primary and secondary prevention of CVD. Pharmacists are ideally situated to engage patients in the discussion of the lack of benefit and possible risk of omega-3 PUFA supplements.
INTRODUCTION:Omega-3 polyunsaturated fatty acids (PUFAs) have purported protective cardiovascular (CV) effects. We sought to assess the evidence available for the use of omega-3 PUFAs for the prevention of cardiovascular disease (CVD). METHODS: A systematic literature search was conducted using MEDLINE and EMBASE from 1999 to 2015. Placebo-controlled, randomized controlled trials (RCTs) that enrolled over 1000 patients with follow-up greater than 1 year and meta-analyses of RCTs were included. RESULTS: Eight RCTs and 2 meta-analyses were included. In patients with preexisting CVD, only 1 of 5 included RCTs demonstrated a reduction in CV events with omega-3 PUFAs; however, the effect size was minimal, and the study was limited by an open-label design and lack of placebo control. Two meta-analyses concluded omega-3 PUFAs do not reduce CV events in addition to standard, evidence-based therapy in patients after myocardial infarction. Of the 3 predominantly primary prevention RCTs, only 1 demonstrated a minor reduction in major coronary events; however, it was also an open-label study. Furthermore, the safety of omega-3 PUFAs should be considered. While data from RCTs have not demonstrated serious safety concerns, omega-3 PUFAs can increase the risk of bleeding and may interact with other medications that affect hemostasis, such as antiplatelet agents and warfarin. DISCUSSION AND CONCLUSION: There is currently a lack of evidence to support the routine use of omega-3 PUFAs in the primary and secondary prevention of CVD. Pharmacists are ideally situated to engage patients in the discussion of the lack of benefit and possible risk of omega-3 PUFA supplements.
Authors: Denise E Bonds; Molly Harrington; Bradford B Worrall; Alain G Bertoni; Charles B Eaton; Judy Hsia; Jennifer Robinson; Traci E Clemons; Lawrence J Fine; Emily Y Chew Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Mauricio G Cohen; Joseph S Rossi; Jennifer Garbarino; Regina Bowling; Alison A Motsinger-Reif; Carl Schuler; Allison G Dupont; Don Gabriel Journal: Thromb Res Date: 2011-05-28 Impact factor: 3.944
Authors: Bernhard Rauch; Rudolf Schiele; Steffen Schneider; Frank Diller; Norbert Victor; Helmut Gohlke; Martin Gottwik; Gerhard Steinbeck; Ulrike Del Castillo; Rudolf Sack; Heinrich Worth; Hugo Katus; Wilhelm Spitzer; Georg Sabin; Jochen Senges Journal: Circulation Date: 2010-11-08 Impact factor: 29.690
Authors: Doo Ri Park; Ryeojin Ko; Suk Hyung Kwon; Bokkee Min; Seong Ho Yun; Manh Heun Kim; John Minatelli; Stephen Hill; Soo Young Lee Journal: J Med Food Date: 2016-12 Impact factor: 2.786
Authors: Angelo Maria Patti; Khalid Al-Rasadi; Rosaria Vincenza Giglio; Dragana Nikolic; Carlo Mannina; Giuseppa Castellino; Roberta Chianetta; Maciej Banach; Arrigo F G Cicero; Giuseppe Lippi; Giuseppe Montalto; Manfredi Rizzo; Peter P Toth Journal: Arch Med Sci Date: 2017-07-19 Impact factor: 3.318